You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
An Advanced Biosensor for Molecular Interaction Studies.
SBC: MOLECULAR SENSING, INC. Topic: NIGMSDESCRIPTION (provided by applicant): Molecular interactions form the foundation of biology and chemistry. They are central to life itself and determine catalytic activity, cellular function, and therapeutic efficacy. The vast majority of diagnostic procedures depend on some type of specific molecular interaction. Therefore, the ability to perform pure liquid-phase molecular binding analysis at hi ...
STTR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health -
Application of CDX-MDM in Pre-Clinical Model of Murine Pulmonary Emphysema
SBC: Covenant Therapeutics LLC Topic: NHLBIDESCRIPTION (provided by applicant): The objective of this proposal is to exploit a newly discovered anti-inflammatory function involving the aminopeptidase activity of the leukotriene A4 hydrolase for the treatment of pulmonary emphysema. The leukotrieneA4 hydrolase is a dual-functioning enzyme with dichotomously opposing functions. As an epoxide hydrolase, it catalyzes the conversion of leukotri ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin
SBC: EYERX RESEARCH, INC. Topic: NEIProject Summary/Abstract Ocular pharmaceuticals predominantly use the topical route of administration, which involves a number of benefits and limitations when compared to systemic drug routes. A major limitation of the ocular topical route is the rapid loss of drug via tearing and nasolacrimal drainage, requiring the use of frequent dosing and high drug concentrations that then create formulation ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Controlling mechanical signal transduction to treat osteoarthritis
SBC: Cytex Therapeutics, Inc. Topic: NIADESCRIPTION (provided by applicant): Controlling mechanical signal transduction to treat osteoarthritis Abstract The TRPV4 calcium (Ca++) permeable ion channel has been shown to be expressed and functional in chondrocytes, the cells responsible for the maintenance of cartilage in weight-bearing joints. Trauma of joints with subsequent damage of cartilage, as well as chronically increased joint loa ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Development of Novel LANCL2-based Anti-diabetic Compounds
SBC: Biotherapeutics, Inc. Topic: NIDDKDESCRIPTION (provided by applicant): About 28.3 million Americans have type II diabetes (T2D) and over 40.1% of middle-aged adults have prediabetes, a condition characterized by impaired glucose tolerance and insulin resistance. Current antidiabetic medications are effective in improving insulin sensitivity, but their chronic administration has significant side effects suc as cardiovascular compli ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Distributed REMD Simulation for Probing Alzheimer Molecular Mechanisms
SBC: PARABON COMPUTATION, INC. Topic: NIADESCRIPTION (provided by applicant): PUBLIC HEALTH RELEVANCE PUBLIC HEALTH RELEVANCE:
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Early Warning system for detecting pre-eclampsia
SBC: CONVERGENT ENGINEERING, INC. Topic: NICHDDESCRIPTION (provided by applicant): Preeclampsia, a hypertensive disorder of pregnancy, is a leading cause of maternal and neonatal morbidity and mortality around the world, responsible for approximately 76,000 maternal and 500,000 infant deaths per year.As a heterogeneous and poorly understood disorder, its pathogenesis and possible treatments are an area of active research. While the majority o ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Enhanced bioscavenger for medical countermeasures against organophosphorus agents
SBC: LUNA INNOVATIONS INCORPORATED Topic: NIEHSDESCRIPTION (provided by applicant): Counteracting the threat of intoxication by organophosphorus nerve agents (OP's) is an important mission for homeland security as well as for treating workers exposed to pesticides. OP's act on acetylcholinesterase to prevent synaptic inactivation, thereby leading to immobilization and death on sustained application. Currently, the most promising stra ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Establishing BRM Polymorphisms as Predictive Biomarkers for Lung Cancer Risk
SBC: ZENAGENE, INC. Topic: NCIDESCRIPTION (provided by applicant): While there is no doubt smoking is a direct causative factor underlying the development of lung cancer, not every smoker develops lung cancer. In fact, only 10-15% of smokers develop this disease, indicating that otherfactors make certain individuals more susceptible to cancer. A number of single nucleotide polymorphisms are known to correlate with the developm ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health -
Evaluation of a new class of molecules for treating MRSA infective endocarditis
SBC: AGILE SCIENCES, INC. Topic: NIAIDDESCRIPTION (provided by applicant): Patients with infective endocarditis (IE) have a poor prognosis with one third of the patients succumbing to the infection within the first year. Treatments for endocarditis involve antibiotic therapy and/or surgery that cost upwards of 100,000 per patient; however, many cases do not respond to the antibiotic treatment and surgery poses high risks. Cases of en ...
STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health